PMN310 has been granted Fast Track Designation by the U.S. FDA for the treatment of Alzheimer’s disease.
Developing a Safe and Effective Alzheimer’s Vaccine
Through the strategic use of disease-associated epitopes identified through our proprietary discovery platform, we aim to develop a safe and effective vaccine to induce a specific immune response against toxic Aβ oligomers (AβOs). An AD vaccine capable of inducing an effective antibody response against pathogenic Aβ could be administered as a preventative measure to at-risk individuals to prevent the development of symptomatic disease or given therapeutically to diagnosed patients to inhibit the progression of AD. ProMIS is collaborating with the Vaccine and Infectious Disease Organization (VIDO) of the University of Saskatchewan to conduct preclinical vaccine development.